Lexaria Completes Dosing in Human Clinical Study HYPER-H21-2

July 27, 2021 7:15 AM

Additionally, second patent award received in JapanKELOWNA, BC / ACCESSWIRE / July 27, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that dosing has been completed in its second human clinical study of 2021.Human clinical study HYPER-H21-2 consisted of 16 human volunteers who were pre- or mildly hypertensive and received three...

Read more

Lexaria Receives US$3,817,643 From Warrant Exercises

July 26, 2021 2:40 PM

KELOWNA, BC / ACCESSWIRE / July 26, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the receipt of US$3,817,643 from the exercise of share purchase warrants (the "Warrants").The Warrants were issued by the Company pursuant to its January 2021 public underwritten offering (the "Offering") whereby the shares and Warrants issued thereunder...

Read more

EV Biologics Unveils NFT Dividend Warrant

July 26, 2021 9:30 AM

NASHVILLE, TN / ACCESSWIRE / July 26, 2021 / EV Biologics Corp, OTC PINK:YECO, today updated shareholders about its NFT dividend Warrant.The Company will distribute one (1) Warrant for every 100 shares of YECO common stock held. Each Warrant will be exercisable for one (1) NFT worth $300. Shareholders will have 90-days (October 28, 2021) to exercise their Warrants to receive their NFTs.YECO's shareholders of record on July 30, 2021 will receive...

Read more

Enzolytics Announces the Appointment of Steve Sharabura as President of its Wholly Owned Subsidiary RobustoMed, Inc (A/K/A ENZO SUB)

July 26, 2021 7:30 AM

COLLEGE STATION, TX / ACCESSWIRE / July 26, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) ("Enzolytics" and the "Company") announced today the appointment of Steve Sharabura as President of the Company's wholly owned subsidiary RobustoMed, Inc. (A/K/A ENZO SUB) based in Atlanta, GA. RobustoMed will be initiating a new business model focused on developing international partnership opportunities for medical development stage drug and product companies....

Read more

Xenetic Biosciences, Inc. Announces $12.5 Million Private Placement Priced at a Premium to Market

July 26, 2021 7:00 AM

FRAMINGHAM, MA / ACCESSWIRE / July 26, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase of 4,629,630 shares of its...

Read more

Applied UV Declares Monthly Preferred Stock Dividend

July 23, 2021 8:00 AM

MOUNT VERNON, NY / ACCESSWIRE / July 23, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, today announced its Board of Directors has authorized the cash dividend to holders of Applied...

Read more

RedHill Settles Movantik(R) Apotex Patent Litigation

July 22, 2021 9:45 AM

RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with ApotexTEL AVIV, ISRAEL and RALEIGH, NC / ACCESSWIRE / July 22, 2021 / RedHill Biopharma Ltd. (Nasdaq:RDHL) ('RedHill' or the 'Company'), a specialty biopharmaceutical company, today announced that RedHill Biopharma Inc., AstraZeneca AB and AstraZeneca Pharmaceuticals LP ('AstraZeneca') and Nektar Therapeutics have entered into a settlement and license agreement with...

Read more

EV Biologics Signs LOI with Lonza Cell & Gene Therapy

July 22, 2021 9:30 AM

NASHVILLE, TN / ACCESSWIRE / July 22, 2021 / EV Biologics Corp., (OTC PINK:YECO) today announced that it has signed a Letter of Intent (LOI) with Lonza Cell & Gene Therapy for Process Development and Gap Analysis for biomanufacturing of a novel therapeutic composition, comprising extracellular vesicles (EVs) and particles, as well as other secreted factors derived from selected stem/progenitor cells, such as mesenchymal stromal cells...

Read more

Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy

July 22, 2021 7:05 AM

All objectives evaluating DehydraTECH™ drug delivery platform successfully achievedKELOWNA, BC / ACCESSWIRE / July 22, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to review its successful 2021 antiviral drug program to date and summarize expected next steps.Lexaria's objectives in its 2021 antiviral drug examination program thus far have...

Read more

Pressure BioSciences Announces Major Business Expansion, Establishing Eco-Friendly Agrochemicals Subsidiary and Initiating Plans to Drive Accretive 2021 Revenue

July 21, 2021 9:25 AM

Significant Order for Environmentally Friendly Agrochemical Material Placed to Fulfill Initial Demand;Subsidiary will House Announced Asset Acquisition from Global Agrochemicals InnovatorSOUTH EASTON, MA / ACCESSWIRE / July 21, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the...

Read more

M2Bio Sciences Food and Beverage Launches CBD Sachets

July 21, 2021 9:15 AM

CAPE TOWN, SA / ACCESSWIRE / July 21, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update:M2Bio Sciences Food & Beverage is pleased to announce the launch of the M2Bio 10mg CBD Dissolvable Powder Sachets. The sachets are the latest innovation from the Company's M2Bio brand...

Read more

Black Bird Biotech to Seek EPA Approval of MiteXstream(TM) Ready-to-Use Formulation

July 21, 2021 8:30 AM

FLOWER MOUND, TX / ACCESSWIRE / July 21, 2021 / Black Bird Biotech, Inc. (OTC PINK:BBBT), manufacturer of plant-based MiteXstreamTM biopesticide, today announced that it will seek EPA approval of the Ready-to-Use formulation of MiteXstreamTM, as a necessary first step to its capitalizing on the lucrative home gardening market."We see MiteXstreamTM as the perfect solution for home gardeners who battle a wide array of pests, molds and mildews,...

Read more

Applied UV Continues International Expansion with Airocide(R) Hospital Installation in Thailand

July 21, 2021 8:30 AM

Airocide® technology helps hospitals to remain open to protect patients, visitors and staffMOUNT VERNON, NY / ACCESSWIRE / July 21, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically,...

Read more

Lexaria's DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3

July 21, 2021 7:05 AM

Possible Benefits for Treating SARS-CoV-2/COVID-19 and mRNA Vaccine Side EffectsKELOWNA, BC / ACCESSWIRE / July 21, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results.This study demonstrated that DehydraTECHTM enabled colchicine, the latest...

Read more

Pressure BioSciences to Expand on Recent UST Platform Breakthroughs and Impending Agrochem Asset Acquisition at Upcoming Emerging Growth Conference

July 20, 2021 10:45 AM

Company Invites Investors, Analysts, and Advisors to Attend Its Real-Time, Interactive UST Platform and Agrochem Asset Acquisition Update, Followed by a Q&A Session, on Wednesday, July 21, 2021SOUTH EASTON, MA / ACCESSWIRE / July 20, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and services to the...

Read more

Sense Appoints Timothy I. Still as President, CEO and Board Member

July 20, 2021 9:00 AM

Appointment of industry veteran to accelerate commercialization of company's instrument-free molecular testing platformBOSTON, MA / ACCESSWIRE / July 20, 2021 / Sense Biodetection, innovator of instrument-free, rapid molecular tests that enable improved patient access and enhanced clinical value through patient-focused decentralized testing, today announced the appointment of Timothy I. Still as President and Chief Executive Officer. Still will...

Read more

Thermic Science Proudly Files All Required Financials & Report Filings Ahead of Schedule to Bring the Company to Pink Current Status and in Compliance with the OTC Market Reporting Changes the New Rule 15c2-11 Amendments before the September 2021 Deadline

July 20, 2021 8:35 AM

NASHVILLE, TN / ACCESSWIRE / July 20, 2021 / Thermic Science International Corporation, formerly known as Omnicanna Health Solutions, Inc. aka Endocan Corporation. (WKN:A1W61J) (ISIN:US29271J1097) (OTC:ENDO), is proud to announce it has officially filed all required financials & reporting requirements ahead of schedule to bring the Company current and in compliance with the OTC Market Exchange and the new Amendments to Rule 15c2-11 before...

Read more

Oncology Pharma, Inc. To Move to Conducting Trials on Licensed IP

July 20, 2021 7:30 AM

SAN FRANCISCO, CA / ACCESSWIRE / July 20, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") is laying out and taking necessary steps to move its licensed IP forward. From obtaining the necessary financing, in order to support studies, to obtaining the data utilizing mouse or rat clinical trials ("Mouse clinical trials" or "MCT") all steps are being established. The Company has decided to pursue moving forward with...

Read more

Enzolytics Announces the Signing of a Letter of Intent with Creative Biolabs, Inc. for Licensing and Commercialization of anti-HTLV-1 Monoclonal Antibodies

July 20, 2021 7:30 AM

COLLEGE STATION, TX / ACCESSWIRE / July 20, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) ("Enzolytics" and the 'Company') announces the signing of a Letter of Intent (LOI) with Creative Biolabs ("Creative") (https://www.creative-biolabs.com) to complete the joint production and commercialization of HTLV-1 monoclonal antibodies by combining the technologies of the companies. There are no effective vaccines against HTLV-1 and no antiviral drugs...

Read more

Sense Appoints Timothy I. Still as President, CEO and Board Member

July 20, 2021 4:00 AM

Appointment of industry veteran to accelerate commercialization of company's instrument-free molecular testing platformCAMBRIDGE, UK / ACCESSWIRE / July 20, 2021 / Sense Biodetection, innovator of instrument-free, rapid molecular tests that enable improved patient access and enhanced clinical value through patient-focused decentralized testing, today announced the appointment of Timothy I. Still as President and Chief Executive Officer. Still...

Read more